Linden Thomas Advisory Services LLC Boosts Stake in Insulet Co. (NASDAQ:PODD)

Linden Thomas Advisory Services LLC lifted its holdings in Insulet Co. (NASDAQ:PODD) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,817 shares of the medical instruments supplier’s stock after purchasing an additional 73 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Insulet were worth $1,262,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Parkside Financial Bank & Trust increased its position in Insulet by 251.0% during the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 123 shares during the last quarter. Allworth Financial LP increased its position in Insulet by 104.5% during the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 92 shares during the last quarter. Wolff Wiese Magana LLC increased its position in Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 134 shares during the last quarter. BluePath Capital Management LLC purchased a new stake in Insulet during the third quarter valued at $31,000. Finally, Lindbrook Capital LLC increased its position in Insulet by 64.1% during the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after acquiring an additional 75 shares during the last quarter.

Insider Buying and Selling at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.90% of the company’s stock.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of research reports. JPMorgan Chase & Co. upped their price objective on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Piper Sandler cut their price target on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Barclays cut their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. Finally, Stifel Nicolaus boosted their price target on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average target price of $243.21.

Insulet Trading Down 0.0 %

Shares of PODD stock opened at $167.25 on Thursday. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $335.91. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62. The stock’s 50 day simple moving average is $172.53 and its two-hundred day simple moving average is $179.35. The company has a market cap of $11.71 billion, a PE ratio of 57.47, a price-to-earnings-growth ratio of 3.01 and a beta of 0.98.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The business had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. During the same period in the prior year, the business posted $0.55 earnings per share. The company’s quarterly revenue was up 37.9% compared to the same quarter last year. Research analysts predict that Insulet Co. will post 3.08 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.